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ABSTRACT
Purpose. Hypertension (HTN) is frequently associated with the use of 
angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such 
as ramucirumab. The aim of this study was to retrospectively evaluate if occurrence of 
HTN is correlated with response to second line treatment with ramucirumab+paclitaxel 
for metastatic gastric cancer.
Methods. Treatment consisted of ramucirumab 8 mg/kg intravenously (iv) on 
days 1 and 15, plus paclitaxel 80 mg/m2 iv on days 1, 8, and 15 of a 28-day cycle. 
Patients received study treatment until disease progression, unacceptable toxicity, 
or withdrawal of consent.
Results. Thirty-four patients were retrospectively evaluated. Among these, 6 
(17.6%) developed grade 3 ramucirumab-induced HTN. These patients had a better 
outcome than those with lesser grades events, with a progression-free survival 
(PFS) of 7.8 months (95% CI 4.4-not reached) versus 4.2 months (95% CI 3.1-5.2) 
(p=0.001). overall survival (OS) was 11.9 months (95% CI 9.3-not reached) in the 
grade 3 HTN group, versus 7.2 months (95% CI 5.9-10.1).
Conclusions. Despite the small number of patients and the retrospective nature 
of the data, our analysis showed that occurrence of ramucirumab-related HTN, in 
particular G3 HTN, predicts response to treatment with ramucirumab+paclitaxel in 
patients with metastatic gastric cancer.
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INTRODUCTION
Gastric cancer is considered one of the main causes of 
cancer-related death worldwide [1, 2]. Unfortunately most 
patients present with metastatic disease and are candidate 
to palliative chemotherapy, with very poor outcome. 
In fact, median overall survival (OS) in these cases is 
limited to 12 months [3, 4]. Recently, ramucirumab, a 
novel anti-angiogenic agent has been approved, initially 
as monotherapy, and subsequently in combination with 
paclitaxel for second line treatment of patients with 
metastatic gastric cancer, in the presence of a good 
performance status [5–8]. Ramucirumab is a human IgG1 
monoclonal antibody against the Vascular Endothelial 
Growth Factor Receptor 2 (VEGFR-2) which prevents 
ligand binding and receptor-mediated pathway activation in 
endothelial cells [9]. As expected from an anti-angiogenic 
agent, hypertension represents a frequent adverse event 
recorded during treatment with ramucirumab. Recently, 
two large meta-analyses quantified the risk of occurrence of 
any grade and high grade (grade 3 and above) hypertension 
in patients treated with ramucirumab [10, 11]. In the phase 
III RAINBOW trial, HTN of any grade was reported in 
25% of patient treated with the combination of paclitaxel 
and ramucirumab, while grade 3 HTN occurred in 15% of 
patients. No grade 4 HTN was reported.
The mechanisms underlying the occurrence of 
ramucirumab-related HTN are not completely clear. 
However it has been hypothesized that ramucirumab-
mediated inhibition of VEGFR-2 could inhibit several 
pathways, including phosphoinositide 3-kinase and Akt, 
as well as reduce the expression of endothelium-derived 
nitric oxide synthase, leading to decrease in nitric oxide 
levels with consequent vasoconstriction and decrease in 
sodium renal excretion. These metabolic changes would 
ultimately result in development of HTN [12–14].
Unfortunately, less than 30% of patients respond 
to ramucirumab, this fact underlying the need to identify 
predictors of treatment efficacy. We performed a retrospective 
analysis to evaluate whether development of HTN in patients 
with metastatic gastric cancer receiving ramucirumab is 
associated with the antitumor effect of the drug.
RESULTS
Patient characteristics
From October 2015 to November 2017, a total of 
34 patients were enrolled in the study. Baseline patient 
characteristics are summarised in Table 1. The majority 
of patients were males (24; 70.6%), with a median age 
of 64 years (range 39–75). In total, 14 (41.2%) patients 
had an ECOG performance status of 0. 14 patients 
(41.1%) received prior surgery, 11 (32.3%) had >2 
sites of metastasis and 13 (38.2%) presented peritoneal 
metastases.
Median PFS was 4.5 months (95% CI 3.2-6.2) and 
median OS was 9.3 months (95% CI 6.8-11), no CR was 
observed, DCR was 76.5% (26/34 patients) (Table 2).
Hypertension and clinical outcome
Thirteen patients (38.2%) presented a previous 
diagnosis of HTN managed with medical treatment. All 
evaluated patients had normal range blood pressure at 
baseline. Nine patients (26.5%) developed HTN during 
treatment (1 patient (2.9%) grade 1, 2 patients (5.9%) 
grade 2 and 6 patients (17.6%) grade 3, no grade 4 was 
reported). Six patients (17.6%) started treatment with 
anti-hypertensive therapy, but no patient discontinued 
ramucirumab as consequence of HNT occurrence.
Patients who developed HTN had a median PFS of 
6.7 months (95% CI 2.2-8.4) in comparison to 4.5 months 
(95% CI 3.1-6.1) for patients with normal blood pressure 
(p=0.02) (Figure 1A). HTN patients had a median OS of 
11.6 months (95% CI 3.1-12.3) compared to 7.2 months 
(95% CI 5-11) for those in the non HTN group (p=0.06) 
(Figure 1B). DCR in HTN patients was 100% compared to 
65.4% in those without HTN (p=0.06) (Table 2).
In particular the benefit was superior in grade 3 
ramucirumab-induced HTN in comparison to all the other 
patients, as median PFS was 7.8 months (95% CI 4.4-not 
reached) in these patients versus 4.2 months (95% CI 3.1-
5.2) in all other patients (p=0.001) (Figure 2A). Median 
OS was 11.9 months (95% CI 9.3-not reached) in patients 
with grade 3 ramucirumab-induced HTN versus 7.2 
months (95% CI 5.9-10.1) in all other patients (p=0.007) 
(Figure 2B). DCR was 100% in patients with grade 3 
drug-induced HTN versus 76.9% in all other patients 
(p=0.17) (Table 2).
Finally Supplementary Figure 1A and 1B reported 
Kaplan-mayer of PFS and OS according any grade of 
HNT.
After adjusting for clinical covariates (peritoneal 
metastases, ECOG PS, number of metastatic sites, 
presence of a primary tumour, time to progression since 
prior therapy, tumour differentiation grade), ramucirumab-
related any-grade HNT showed an hazard ratio (HR) of 
0.34 for PFS (HR=0.34, 95% CI 0.13-0.37, p=0.02) and of 
0.49 for OS (HR=0.49, 95% CI 0.22-1.11, p=0.09). Grade 
3 HNT showed a HR of 0.21 for PFS (HR=0.21, 95% CI 
0.12-0.42, p=0.002) and of 0.26 for OS (HR=0.26, 95% 
CI 0.19-0.76, p=0.01), confirming that grade 3 HNT is an 
independent prognostic factor for response to treatment.
DISCUSSION
Angiogensis is still considered one of the main 
actionable targets of anticancer therapies. HTN is a 
common “on-target” adverse event of the treatment with 
antiangiogenic drugs and may represent a possible clinical 
predictive marker of treatment efficacy.
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Ramucirumab is an antiangiogenic monoclonal 
antibody specific for the VEGFR-2. Whilst the occurrence 
of HTN has rarely led to discontinuation of treatment [11], 
a recent meta-analyses defined the risk of ramucirumab-
related HNT [11], in particular the 9% of patients 
experienced grade 3 HNT with a relative risk:3.7. In 
2017, a meta- with the anti-VEGF bevacizumab reported 
an HNT incidence of 9.3% and a relative risk: 4.89 [15], 
while for the “VEGF-trap” aflibercept, another meta-
analysis patients reported a summary incidences of high-
grade HNT of 17.4 % (OR 4.97) [16]. From these data 
it seems that ramucirumab may induce lesser HTN than 
other anti-VEGF compounds.
The mechanisms behind the development of 
HTN from ramucirumab are similar to those described 
for other antiangiogenic agents and include: decreased 
production of nitric oxide in the wall of arterioles and 
other resistance vessels [17], increased activation of the 
endothelin-1 system [18], and/or capillary rarefaction 
[19]. However, ramucirumab blocks angiogenesis by a 
different mechanism of action compared with other anti-
angiogenetis agents, the unique receptor-binding activity 
of ramucirumab on VEGFR2, that is different respect 
ligand-binding or “the VEGF-trap”, may explain the 
diversity of HNT incidence from ramucirumab compared 
with bevacizumab or aflibercept.
Cumulative data show that bevacizumab-induced 
HTN appears to be associated with its efficacy. Scartozzi et 
al evaluated 39 patients with metastatic colorectal cancer 
treated with bevacizumab as part of front-line therapy 
[20] showing an in increase in RR and PFS observed in 
the group of patients who developed bevacizumab-related 
HTN, however, no statistically significant difference 
was observed in OS. Österlund et al showed that HTN 
predicted bevacizumab treatment efficacy and OS [21]. 
Recently, HTN grade 2-3 was predictive of response to 
treatment with bevacizumab in metastatic colorectal 
cancer but not of OS [22]. Finally, similar studies were 
published for patients with breast, lung and renal cancer 
confirming the role of bevacizumab-HNT as a predictive 
biomarker [23–25]. Unfortunately, little data are available 
about HNT and ramucirumab efficacy in metastatic gastric 
cancer. In this retrospective study, a correlation emerged 
between the development of HTN during treatment with 
ramucirumab and the survival outcomes of patients with 
metastatic gastric cancer. Patients who developed HTN 
had a better PFS, RR and OS than those without HTN.
Of note, patients with grade 3 ramucirumab-related 
HTN showed a significantly higher benefit and better 
outcomes in comparison to any other patients (Figure 2). 
In this context, a more recent pharmacokinetic analysis 
[26] of both REGARD and RAINBOW phase III trials, 
aimed at evaluating exposure-efficacy and exposure-
safety relationships of ramucirumab, showed that higher 
ramucirumab exposure was associated with longer OS 
and PFS. Specifically, in the 321 patients treated with 
ramucirumab+paclitaxel on the RAINBOW study, 
grade 3 and above HNT and other adverse events such 
as leukopenia and neutropenia significantly correlated 
with drug steady state, with increased exposure leading 
to increased incidence of these side effects. In line with 
these data, our grade 3 HNT patients showed a better 
outcome compared to patients with HNT of lesser grades 
or no HNT. Unfortunately, the small sample size did not 
allow further analysis and stratification by grades and 
Table 1: Patient characteristics
No. of patients 34
Age, years
 Median 64
 Range 39-75
Sex
 Male 24
 Female 10
ECOG PS
 0 14
 1 20
Tumor location
 Stomach 26
 Gastroesophageal junction 8
Differentiation
 Well differentiated 3
 Moderate 11
 Poorly differentiated 20
Primary tumor resected
 Yes 14
 No 20
Previous treatment
 Triplet 8
 Doublet 24
 HER2 2
Time to progressive disease on 
first-line therapy
 <6 months 20
  ≥6 months 14
Number of metastatic sites
 0–2 23
  ≥3 11
 Peritoneal metastases 13
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Table 2: Best response according HNT grade
All patients
(n=34)
G0
(n=25)
G1
(n=1)
G2
(n=2)
G3
(n=6)
PR 9 7 0 0 2
SD 17 10 1 2 4
PR + SD 26 17 1 2 6
PD 6 6 0 0 0
NE 2 2 0 0 0
PFS 
(months)
4.5 4.5 NE 2.2 7.8
OS (months) 9.3 7.2 NE 3.1 11.9
Abbreviations: progression free survival (PFS); overall survival (OS), partial response (PR), stable disease (SD), 
progression disease (PD), not evaluable (NE)
Figure 1: (A) Estimated PFS for ramucirumab+paclitaxel in patients with hypertension (blue) or without (red); (B) Estimated OS for 
ramucirumab+paclitaxel in patients with hypertension (blue) or without (red).
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more studies are awaited to evaluate the significance of 
lower grade on target adverse events. Furthermore, whilst 
another exploratory analysis of efficacy and safety of 
ramucirumab conducted in East Asian patients from the 
RAINBOW trial [27] confirmed the positive relationship 
between efficacy and ramucirumab exposure, patients with 
higher ramucirumab steady state had higher incidence of 
grade ≥3 leukopenia and neutropenia, but not HNT. This 
last data may require a specific analysis in prospective 
studies, taking into account the genetic differences 
between East Asian and European patients.
It is well known that HNT from antiangiogenic 
agents is readily managed with anti-hypertension 
medications [11] and in the near future further 
Figure 2: (A) Estimated PFS for ramucirumab+paclitaxel in patients with hypertension grade 3 (blue) or hypertension <3 (red); (B) 
Estimated OS for ramucirumab+paclitaxel in patients with hypertension grade 3 (blue) or hypertension <3 (red).
Oncotarget22337www.oncotarget.com
studies will be investigating the potential impact 
of hypertension therapies on treatment efficacy 
in metastatic gastric cancer patients treated with 
ramucirumab.
The present study has several limitations such as 1) 
the retrospective nature of the data, 2) the small number 
of patients evaluated and 3) the absence of a control arm 
(patients not receiving ramucirumab). Therefore, it is 
difficult to draw definitive conclusions and the clinical 
characteristics of patients may also impact on the findings 
especially for the multivariate analysis. Nonetheless 
we observed a strong correlation between occurrence 
of higher grade HTN and response to therapy with 
ramucirumab.
In conclusion, ramucirumab-induced HTN 
(mainly grade 3) is an independent predictor of 
treatment efficacy and survival in patients with 
metastatic gastric cancer treated with the combination 
of ramucirumab+paclitaxel. Prospective large-scale 
trials are needed to further confirm these results and 
examine the significance of on target hypertension as a 
predictive marker of response to therapy.
PATIENTS AND METHODS
Eligibility criteria
The study retrospectively evaluated patients with 
histologically proven advanced gastric cancer, who had 
documented objective radiological or clinical disease 
progression during or within 4 months from the last 
dose of first-line platinum and fluoropyrimidine doublet, 
with or without anthracycline. Patients eligibility criteria 
included 18 years of age or more, Eastern Cooperative 
Oncology Group performance status of 0-1, bi-
dimensionally measurable disease, a life expectancy of 
at least 3 months, adequate haematological parameters 
(an absolute neutrophil count ≥ 1.5 x 109/l and a platelet 
count ≥ 100 x 109/l), creatinine and total bilirubin levels 
<1.25 times the upper normal limit, aspartate and alanine 
aminotransferase <3.0 times the upper normal limit and 
absence of a second primary tumour other than non-
melanoma skin cancer or in-situ cervical carcinoma. 
Patients with operable metastatic disease were excluded 
from the study, as were those with severe cardiac 
dysfunction, chronic diarrhoea or sites of uncontrolled 
infection and patients with a history of gastrointestinal 
perforation, fistulae, arterial thromboembolic event 
within the previous 6 months, significant gastro-intestinal 
bleeding, any significant venous thromboembolism 
(within 3 months before enrolment) or poorly controlled 
hypertension defined as systolic blood pressure ≥ 160 
mmHg  or  diastolic  blood  pressure  ≥  95 mmHg. This 
study was approved by the local ethical and scientific 
committee and all patients gave their written informed 
consent.
Patient evaluation
The pre-treatment evaluation, performed within 2 
weeks before study entry, included a detailed history and 
physical examination, a complete blood cell count with 
differential and platelet counts, whole-blood chemistry 
and computed tomography (CT) scans, and/or magnetic 
resonance imaging (MRI) of the chest and abdomen. 
Blood pressure measurements were recorded before the 
infusion of ramucirumab and a daily record of the blood 
pressure values was kept by the patient. The highest value 
of arterial blood pressure recorded was taken into account 
to define the grade of ramucirumab-induced arterial HTN 
according to the grading of the National Cancer Institute—
Common Toxicity Criteria toxicity scale V.4.2 [28]. 
Treatment response by means of CT scan and/or MRI was 
evaluated every 3 cycles or sooner if clinically indicated. 
Tumour response was assessed using RECIST 1.1 criteria 
[29].
Treatment delivery
Treatment consisted of ramucirumab 8 mg/kg 
intravenously (i.v.) on days 1 and 15, plus paclitaxel 80 
mg/m2 i.v. on days 1, 8 and 15 of a 28-day cycle. Patients 
received study treatment until disease progression, 
unacceptable toxicity or consent withdrawal.
Statistical considerations
This is a retrospective cohort study aiming to 
investigate the efficacy of ramucirumab in patients who 
developed on-target HTN in comparison to patients 
without HTN. Primary end-point was progression free 
survival (PFS), calculated as the time from the first 
ramucirumab infusion to disease progression or death. 
Secondary end points included: overall survival (OS), 
measured from the date of treatment start to the date of 
death, and disease control rate (DCR), expressed as the 
proportion of patients who achieved complete response 
(CR), partial response (PR) and stable disease (SD) 
according RECIST criteria. Mean, median, standard 
deviation and minimum and maximum values were 
reported for continuous variables, while count and 
proportion were reported for non-continuous variables. 
Kaplan-Meier method was used to determine PFS and 
OS. Long-rank test was performed to analyse PFS and OS 
in relation to the development of HTN. Comparisons of 
PFS and OS between groups were performed using Cox 
Regression. Data on patients who were lost to follow-up 
were censored at the time of the last evaluation. After 
univariate analysis, a multivariable Cox regression model 
(including peritoneal metastases, ECOG PS, number of 
metastatic sites, presence of a primary tumour, time to 
progression since prior therapy, tumour differentiation 
grade) was used to adjust for these potentially confounding 
factors. The threshold for statistical significance was 
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established at P<0.05. Statistical analysis was performed 
using STATA software.
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